US CAR T Market Situation, Landscape, and Outlook

Four years after the launch of the first CAR T-cell therapy, we now have five on the market and a host of others on the way. This white paper maps out key learnings and implications from the pioneers, what we can expect to see over the next several years in the category, and where we still have questions remaining to be answered. (August 2021)